Search results for "malattie"

showing 10 items of 1963 documents

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.

2009

Purpose. To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines. Methods. The study, double-blinded, randomised, assessed intravenous infusion of LPC 1.2 g/day in combination with PGE-1, 60 mg/day (LPC group: 37 patients), or PGE-1 only (control group: 38 patients) in a total of 75 patients suffering from CLI. Treatment duration was 20 days. We evaluated rest pain, maximum walking distance (MWD) and skin ulcer size. Results. In both groups we observed a significant reduction in pain score and ulcer size and an increase in MWD. In the patients treated with the combination, the improvement was greater…

MaleSettore MED/09 - Medicina InternaCardiotonic AgentsVasodilator AgentsProstaglandin E1IschemiaPainWalkinglaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawIschemiaCarnitinemedicineHumansPharmacology (medical)CarnitineAlprostadilProstaglandin E1Infusions IntravenousAgedPharmacologyLegCritical Limb Ischemiabusiness.industryTherapeutic effectLeg UlcerDrug SynergismGeneral MedicineCritical limb ischemiaL-PropionylcarnitineSkin ulcerMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment OutcomechemistryAnesthesiaChronic Diseaselipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugCardiovascular drugs and therapy
researchProduct

Serum uric acid is not independently associated with plasma renin activity and plasma aldosterone in hypertensive adults

2017

Background and Aims In experimental investigations conducted in rats, raising serum uric acid (SUA) levels resulted in the stimulation of intrarenal renin expression. Studies in humans exploring the association of SUA with plasma renin activity (PRA) yielded conflicting results. Moreover, little is known about the relationship of SUA with plasma aldosterone concentration (PAC). The study aimed to assess the relationship between SUA levels, PRA, and PAC and the influence of age, gender, body mass index (BMI), and hyperuricemia on these relationships in subjects with essential hypertension (EH). Methods and Results We enrolled 372 hypertensive patients (mean age 45 ± 12 years, men 67%) with u…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologyEssential hypertensionKidneyPlasma renin activityRenin-Angiotensin Systemchemistry.chemical_compound0302 clinical medicineRisk FactorsReninNutrition and Dietetic030212 general & internal medicineHyperuricemiaAldosteroneAdiposityNutrition and DieteticsAldosteroneAge FactorsMiddle AgedHypertensionBlood pressureFemaleCardiology and Cardiovascular MedicineAdultArterial hypertensionmedicine.medical_specialtyRenal functionHyperuricemiaEssential hypertension03 medical and health sciencesSex FactorsPlasma renin activityPlasma aldosteroneInternal medicinemedicineHumansSettore MED/14 - NefrologiaCreatinineChi-Square Distributionbusiness.industrymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyCross-Sectional StudieschemistryMultivariate AnalysisLinear ModelsUric acidbusinessBody mass indexUric acidBiomarkers
researchProduct

Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease

2014

Plasma aldosterone concentrations (PACs) are often increased in the advanced stages of chronic kidney disease (CKD); however, PAC has not been fully investigated in early CKD. Moreover, little is known about the relationship between aldosteronemia and left ventricular (LV) mass in subjects with mild-to-moderate CKD. The study objectives were to analyze PAC, LV mass (LVM), LV geometry and their relationships, in a group of hypertensive patients with stage I-III CKD. One hundred ninety-five hypertensive patients with stage I-III CKD were enrolled and compared with a control group of 82 hypertensive patients without renal dysfunction. LVM was higher in subjects with CKD than in the control gro…

MaleSettore MED/09 - Medicina InternaPhysiologyBlood PressureKidney Function Testsurologic and male genital diseasesMuscle hypertrophychemistry.chemical_compoundAldosteroneAldosteroneMedicine (all)ConfoundingMiddle Agedfemale genital diseases and pregnancy complicationsleft ventricular geometrymedicine.anatomical_structureleft ventricular maCreatinineHypertensionCardiologyFemaleHypertrophy Left VentricularWaist CircumferenceCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyRenal functionYoung AdultInternal medicineCKDInternal MedicinemedicineHumansRenal Insufficiency ChronicAgedSettore MED/14 - NefrologiaCreatinineKidney Function Testbusiness.industryCardiovascular riskmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareUric AcidEndocrinologyBlood pressurechemistryVentricleplasma aldosteronebusinessKidney diseaseHypertension Research
researchProduct

Subclinical atherosclerosis and fetuin-A plasma levels in essential hypertensive patients

2012

The intima-media thickness (IMT) is considered as a surrogate marker for atherosclerotic disease. The aim of this study was to analyze the relationship of carotid IMT with fetuin-A in patients with essential hypertension (EH) and normal renal function. The plasma levels of fetuin-A, interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and the biomarker of oxidative stress 8-iso-PGF2alpha were assayed in samples from 105 untreated EH patients. Carotid IMT measurements were also performed. EH was studied overall and after dividing in EH with IMT ≥ and 0.9 mm (AUC (area under the curve) 0.738, P<0.0001). Our results suggest that in EH, fetuin-A is associated with the IMT independently of oxid…

MaleSettore MED/09 - Medicina Internaalpha-2-HS-GlycoproteinPhysiologyDinoprostKidneyEssential hypertensionmedicine.disease_causeCarotid Intima-Media ThicknessGastroenterologyatherosclerosiRisk FactorsMedicinebiologyArea under the curveMiddle Agedmusculoskeletal systemHypertensioncardiovascular systemRegression AnalysisBiomarker (medicine)FemaleEssential HypertensionCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyRenal functionPredictive Value of TestsInternal medicineInternal MedicineHumanscardiovascular diseasesintima-media thicknessInterleukin 6Settore MED/14 - NefrologiaInterleukin-6Tumor Necrosis Factor-alphabusiness.industrySurrogate endpointAtherosclerosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareFetuinfetuin-AOxidative StressCross-Sectional StudiesEndocrinologyinflammationCase-Control Studiesbiology.proteinbusinessBiomarkersOxidative stressHypertension Research
researchProduct

Evaluating the efficacy of current treatments for reducing postoperative ileus: a randomized clinical trial in a single center.

2014

AIM: Postoperative ileus has been considered an inevitable consequence of abdominal surgery. The aim of the study was to investigate the efficacy of same treatments in resolving postoperative ileus in various surgical approaches. METHODS: A total of 360 patients underwent abdominal surgery, and was divided into four groups: videolaparoscopic cholecystectomy, laparotomic colo-rectal surgery, laparotomic Hartmann procedure, laparotomic gastric surgery. In each group, patients received different postoperative treatments: chewing gum, olive oil, both, and water. Each group was compared with a control group. RESULTS: In patients who underwent videolaparoscopic cholecystectomy, median postoperati…

MaleSettore MED/17 - Malattie InfettiveColonAbdomen; Chewing gum; Ileus; Olive oil; Surgery; SurgeryIleuChewing gum olive oil ileus abdomen surgeryEatingIleusPostoperative ComplicationsAbdomenFlatulenceHumansPlant OilsDefecationDigestive System Surgical ProceduresAgedLaparotomySettore MED/12 - GastroenterologiaStomachRectumWaterRecovery of FunctionLength of StayMiddle AgedChewing gumSettore MED/18 - Chirurgia GeneraleCholecystectomy LaparoscopicFemaleSurgeryGastrointestinal MotilityOlive oil
researchProduct

Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma

2017

Abstract Background Bronchial thermoplasty (BT) is a non-pharmacological intervention for severe asthma whose mechanism of action is not completely explained by a reduction of airway smooth muscle (ASM). In this study we analyzed the effect of BT on nerve fibers and inflammatory components in the bronchial mucosa at 1 year. Methods Endobronchial biopsies were obtained from 12 subjects (mean age 47 ± 11.3 years, 50% male) with severe asthma. Biopsies were performed at baseline (T0) and after 1 (T1), 2 (T2) and 12 (T12) months post-BT, and studied with immunocytochemistry and microscopy methods. Clinical data including Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnai…

MaleSevere asthmaBronchial biopsieBiopsymedicine.medical_treatmentVital CapacityGastroenterologyBronchial thermoplasty0302 clinical medicineBronchoscopyQuality of lifeForced Expiratory VolumeSubmucosa030212 general & internal medicinemedicine.diagnostic_testCD68Middle AgedNerve fiberAblationImmunohistochemistryResidual VolumeTreatment Outcomemedicine.anatomical_structureAsthma Control QuestionnaireFemaleResearch ArticleAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyBronchiBronchial biopsiesNerve fibersRespiratory MucosaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicineBronchoscopymedicineHumansAgedAsthmalcsh:RC705-779Bronchial thermoplastybusiness.industryTotal Lung Capacitylcsh:Diseases of the respiratory systemmedicine.diseaseAsthmarespiratory tract diseases030228 respiratory systembusinessBMC Pulmonary Medicine
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct

The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in …

2017

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, pati…

MaleSex FactorRate ratio030226 pharmacology & pharmacyGonadal Steroid HormoneSeverity of Illness Index0302 clinical medicineOutpatient clinicAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; PsoriasisPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyGonadal Steroid HormonesOriginal ResearchIncidence (epidemiology)IncidenceMedicine (all)General MedicineMiddle AgedMenopausePostmenopauseItalyCyclosporineFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanAdultmedicine.medical_specialtyAdolescentAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult; Pharmacology (medical)Adverse drug reactionDermatology03 medical and health sciencesYoung AdultSex FactorsInternal medicineSeverity of illnessmedicineHumansPsoriasisRisk factorAdverse effectPsoriasibusiness.industryGendermedicine.diseaseSurgeryAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Medicine (all); Pharmacology (medical)Prospective StudiebusinessAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis;
researchProduct

Authors’ response

2012

Claudio Sorino,1,2 Salvatore Battaglia,1 Nicola Scichilone,1 Claudio Pedone,3 Raffaele Antonelli-Incalzi,3 Duane Sherrill,4 Vincenzo Bellia11Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Division of Pulmonology, S Anna Hospital, Como, Italy; 3Chair of Geriatrics, University Campus Bio-Medico, Roma, Italy; 4Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USABackground: The choice between lower limit of normal or fixed value of forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC) &amp;lt; 0.70 as the criterion for confirming airway obstruction is an open issue. In t…

MaleSpirometryVital capacitymedicine.medical_specialtyLetterCross-sectional studyVital CapacityInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioForced Expiratory VolumeInternal medicinemedicineHumansAgedAged 80 and overlcsh:RC705-779COPDmedicine.diagnostic_testbusiness.industryGeneral MedicineHealthy elderlylcsh:Diseases of the respiratory systemAirway obstructionrespiratory systemmedicine.diseaselung function test elderlyRespiratory Function TestsSurgeryrespiratory tract diseasesCross-Sectional StudiesItalyCardiologyFemalebusinesscirculatory and respiratory physiologyInternational Journal of COPD
researchProduct